Scientists have determined that a subset of immune cells may cause malaria
patients to contract the severe form of the disease, suffering worse
symptoms. Led by Monash University immunologist Professor Magdalena
Plebanski, the international team found that patients with the severe form
of
malaria have a specific type of cell in their body that people with
uncomplicated disease do not. This type of cell, described in an article
published
April 24 in the open access journal PLoS Pathogens, turns off the immune
system and can allow the parasite to grow uncontrollably.
The research team included scientists from Monash University's Department
of Immunology; Menzies School of Health Research in Darwin; National
Institute of Health Research and Development (NIHRD), Ministry of Health,
Jakarta, Indonesia as well as researchers from NIHRD-MSHR Collaborative
Research Program and District Health Authority, Timika, Papua, Indonesia;
Centre for Vaccinology and Tropical Medicine, Nuffield Department of
Clinical Medicine, Churchill Hospital, Oxford, UK and Queensland Institute
of Medical Research, Brisbane, Australia.
Professor Plebanski and her team investigated the relationship between
regulatory T (Treg) cells, parasite burden, and disease severity in adult
malaria patients with either uncomplicated or severe malaria. When
comparing Treg cell characteristics, the team was able to identify
elevated levels
of a new highly suppressive subset of Treg cells in those patients with
severe malaria.
"The regulatory (Treg) cell subset associated with severe disease in
humans expresses a unique combination of surface markers, including TNFRII
.
Regulatory T (Treg) cells are a small specialized subset of immune cells
that suppress the activation and expansion of effector immune cells, which
partake in parasite elimination," Professor Plebanski said.
"Our results indicate that severe malaria is accompanied by the induction
of highly suppressive Treg cells that can promote parasite growth and
caution against the induction of these Treg cells when developing
effective malaria vaccines."
It is estimated that 500 million people live in areas where there is a
risk of getting malaria. The severe form of the disease causes death in
1-3
million people each year. Professor Plebanski said until now it had been
largely unknown what bodily factors enable some patients to fight and
survive
the disease, while other patients contract the severe form of the disease
and sometimes die.
"Targeting this cell type may lead to new drugs and immunotherapeutics
against malaria. Further studies are needed to determine if this new cell
may
also be promoting severe forms of other inflammatory diseases," Professor
Plebanski said.
CITATION:
"Parasite-Dependent Expansion of TNF Receptor II - Positive Regulatory T Cells with Enhanced Suppressive Activity in Adults with Severe Malaria."
Minigo G, Woodberry T, Piera KA, Salwati E, Tjitra E, et al. (2009)
PLoS Pathog 5(4): e1000402.
doi:10.1371/journal.ppat.1000402
Source
PLoS Pathog